HRP20121074T1 - Derivati kinolina i njihovi farmaceutski sastavi - Google Patents
Derivati kinolina i njihovi farmaceutski sastavi Download PDFInfo
- Publication number
- HRP20121074T1 HRP20121074T1 HRP20121074TT HRP20121074T HRP20121074T1 HR P20121074 T1 HRP20121074 T1 HR P20121074T1 HR P20121074T T HRP20121074T T HR P20121074TT HR P20121074 T HRP20121074 T HR P20121074T HR P20121074 T1 HRP20121074 T1 HR P20121074T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- hydroxy
- indan
- ylamino
- hydroxyethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj, naznačen time, da ima formulu I
[image]
u obliku kristalne soli ili kristalnog solvata, gdje je W skupina formule
[image]
i A je acetat ili ksinafoat.
2. Spoj prema zahtjevu 1, naznačen time, da je to kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-acetata.
3. Spoj prema zahtjevu 2, naznačen time, da u svojem uzorku difrakcije X-zraka ima čvrstu vršnu vrijednost (2θ) do 4,3°.
4. Spoj prema zahtjevu 2, naznačen time, da u svojem uzorku difrakcije X-zraka ima sljedeće karakteristične difrakcijske linije (2θ): 4,3 °, 8,4 °, 11,4 °, 15,1 °, 17,0 °, 18,6 °, 19,1 °, 19,7 °, 20,5 °, 22,9 °, 23,3 °, 23,5 °, 24,6 °, 25,6 °, 28,9 ° i 30,5°.
5. Spoj prema zahtjevu 1, naznačen time, da je to kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-ksinafoata.
6. Spoj prema zahtjevu 5, naznačen time, da u svojem uzorku difrakcije X-zraka ima čvrstu vršnu vrijednost (2θ) do 4,1°.
7. Spoj prema zahtjevu 5, naznačen time, da u svojem uzorku difrakcije X-zraka ima sljedeće karakteristične difrakcijske linije (2θ): 4,1 °, 10,0 °, 12,2 °, 12,9 °, 18,2 °, 20,9 ° i 25,9°.
8. Farmaceutski sastav, naznačen time, da kao aktivni sastojak, obuhvaća učinkovitu količinu spoja prema zahtjevu 1, opcijski zajedno s farmaceutski prihvatljivim nosačem.
9. Farmaceutski sastav prema zahtjevu 8, naznačen time, da je aktivni sastojak kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-acetata ili kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-ksinafoata.
10. Farmaceutski sastav prema zahtjevu 8 ili zahtjevu 9, naznačen time, da je u obliku koji se može inhalirati.
11. Farmaceutski sastav prema zahtjevu 8, naznačen time, da kao aktivni sastojak, nadalje obuhvaća jednu, dvije, tri ili više protuupalnih, bronhodilatornih, antihistaminskih/protualergijskih ili antitusivnih ljekovitih tvari.
12. Farmaceutski sastav prema zahtjevu 11, naznačen time, da kao aktivni sastojak, nadalje obuhvaća jedan od spojeva ili oba spoja mometason furoata i glikopirolata.
13. Spoj prema zahtjevu 1, naznačen time, da se upotrebljava za liječenje upalnih ili opstrukcijskih bolesti dišnih puteva.
14. Kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-acetata, naznačen time, da se upotrebljava za liječenje astme ili kronične opstrukcijske plućne bolesti.
15. Kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-ksinafoata, naznačen time, da se upotrebljava za liječenje astme ili kronične opstrukcijske plućne bolesti.
16. Postupak proizvodnje spoja prema zahtjevu 1, naznačen time, da obuhvaća:
(i) reakciju slobodne baze s octenom kiselinom, za proizvodnju spojeva formule I, gdje A je acetat; ili
(ii) reakciju slobodne baze s 1-hidroksi 2-naftolnom kiselinom, za proizvodnju spojeva formule I, gdje A je ksinafoat.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0613160A GB0613160D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| GB0613156A GB0613156D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| GB0613158A GB0613158D0 (en) | 2006-06-30 | 2006-06-30 | Organic compounds |
| GB0613159A GB0613159D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| EP06117129A EP1878722A1 (en) | 2006-07-13 | 2006-07-13 | Quinolinone derivatives and their pharmaceutical compositions |
| PCT/EP2007/056632 WO2008000839A1 (en) | 2006-06-30 | 2007-07-02 | Quinolinone derivatives and their pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121074T1 true HRP20121074T1 (hr) | 2013-01-31 |
Family
ID=38610531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121074TT HRP20121074T1 (hr) | 2006-06-30 | 2007-07-02 | Derivati kinolina i njihovi farmaceutski sastavi |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8198450B2 (hr) |
| EP (1) | EP2044025B1 (hr) |
| JP (1) | JP5253392B2 (hr) |
| KR (1) | KR101402398B1 (hr) |
| CN (1) | CN101479245B (hr) |
| AU (1) | AU2007264946B2 (hr) |
| BR (1) | BRPI0713951B8 (hr) |
| CA (1) | CA2654801C (hr) |
| CY (3) | CY1113733T1 (hr) |
| DK (1) | DK2044025T3 (hr) |
| ES (1) | ES2396987T3 (hr) |
| FI (2) | FIC20200047I1 (hr) |
| FR (2) | FR20C1054I1 (hr) |
| HR (1) | HRP20121074T1 (hr) |
| HU (2) | HUS2000043I1 (hr) |
| IL (1) | IL195796A (hr) |
| LT (2) | LTC2044025I2 (hr) |
| LU (2) | LUC00185I2 (hr) |
| MA (1) | MA30540B1 (hr) |
| MX (1) | MX2008016542A (hr) |
| MY (1) | MY150468A (hr) |
| NO (3) | NO341709B1 (hr) |
| NZ (1) | NZ573292A (hr) |
| PL (1) | PL2044025T3 (hr) |
| PT (1) | PT2044025E (hr) |
| SI (1) | SI2044025T1 (hr) |
| WO (1) | WO2008000839A1 (hr) |
| ZA (1) | ZA200809948B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2266656A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| CN101861314B (zh) | 2007-09-05 | 2013-07-24 | 里格尔制药公司 | N4-[(2,2-二氟-4h-苯并[1,4]*嗪-3-酮)-6-基]-5-氟-n2-[3-(甲基氨基羰基亚甲基氧基)苯基]-2,4-嘧啶二胺的1-羟基-2-萘甲酸盐 |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| CN105209013B (zh) | 2013-03-14 | 2019-04-26 | 诺华股份有限公司 | 喷雾干燥制剂经喷雾混合的脱非晶化 |
| ES2747905T3 (es) | 2015-09-29 | 2020-03-12 | Inke Sa | Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona |
| CN110724095B (zh) * | 2019-09-12 | 2023-06-09 | 上海方予健康医药科技有限公司 | 一种茚达特罗乙酸盐的制备方法 |
| WO2026027448A1 (en) | 2024-07-29 | 2026-02-05 | Inke, S.A. | Micronization process of indacaterol acetate |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05202301A (ja) * | 1991-08-29 | 1993-08-10 | Yamamoto Chem Inc | ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料 |
| EP0688871A3 (en) * | 1994-06-24 | 1998-07-08 | Quest International B.V. | Preparation of phytosphingosine derivative |
| FR2777279B1 (fr) * | 1998-04-08 | 2004-08-13 | Hoechst Marion Roussel Inc | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| GB0029562D0 (en) * | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0127430D0 (en) | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| US7417051B2 (en) | 2002-04-12 | 2008-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising betamimetics and a novel anticholinergic |
| US7250426B2 (en) | 2002-11-29 | 2007-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Tiotropium-containing pharmaceutical combination for inhalation |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| TWI324150B (en) | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
| TWI324151B (en) | 2003-04-02 | 2010-05-01 | Novartis Ag | Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones |
| AU2004226824B2 (en) | 2003-04-04 | 2008-05-01 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| PT1869049E (pt) | 2005-03-21 | 2009-05-26 | Lilly Co Eli | Compostos de imidazopiridazina |
| GB0511065D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
-
2007
- 2007-07-02 DK DK07819899.1T patent/DK2044025T3/da active
- 2007-07-02 JP JP2009517241A patent/JP5253392B2/ja active Active
- 2007-07-02 MX MX2008016542A patent/MX2008016542A/es active IP Right Grant
- 2007-07-02 CA CA2654801A patent/CA2654801C/en active Active
- 2007-07-02 SI SI200731103T patent/SI2044025T1/sl unknown
- 2007-07-02 US US12/304,617 patent/US8198450B2/en active Active
- 2007-07-02 EP EP07819899A patent/EP2044025B1/en active Active
- 2007-07-02 ES ES07819899T patent/ES2396987T3/es active Active
- 2007-07-02 PT PT78198991T patent/PT2044025E/pt unknown
- 2007-07-02 HR HRP20121074TT patent/HRP20121074T1/hr unknown
- 2007-07-02 MY MYPI20085146 patent/MY150468A/en unknown
- 2007-07-02 KR KR1020087031819A patent/KR101402398B1/ko active Active
- 2007-07-02 AU AU2007264946A patent/AU2007264946B2/en active Active
- 2007-07-02 PL PL07819899T patent/PL2044025T3/pl unknown
- 2007-07-02 WO PCT/EP2007/056632 patent/WO2008000839A1/en not_active Ceased
- 2007-07-02 CN CN2007800244042A patent/CN101479245B/zh active Active
- 2007-07-02 BR BRPI0713951A patent/BRPI0713951B8/pt active IP Right Grant
- 2007-07-02 NZ NZ573292A patent/NZ573292A/en unknown
-
2008
- 2008-11-24 ZA ZA2008/09948A patent/ZA200809948B/en unknown
- 2008-12-08 IL IL195796A patent/IL195796A/en active IP Right Grant
- 2008-12-30 MA MA31527A patent/MA30540B1/fr unknown
-
2009
- 2009-01-20 NO NO20090312A patent/NO341709B1/no active Protection Beyond IP Right Term
-
2012
- 2012-05-04 US US13/463,978 patent/US20120316142A1/en not_active Abandoned
- 2012-11-29 CY CY20121101169T patent/CY1113733T1/el unknown
-
2020
- 2020-11-12 FR FR20C1054C patent/FR20C1054I1/fr active Active
- 2020-11-18 HU HUS2000043C patent/HUS2000043I1/hu unknown
- 2020-11-20 LU LU00185C patent/LUC00185I2/fr unknown
- 2020-11-23 NO NO2020041C patent/NO2020041I1/no unknown
- 2020-11-25 LT LTPA2020535C patent/LTC2044025I2/lt unknown
- 2020-11-26 CY CY2020038C patent/CY2020038I1/el unknown
- 2020-11-27 FI FIC20200047C patent/FIC20200047I1/fi unknown
- 2020-12-07 LU LU00188C patent/LUC00188I2/en unknown
- 2020-12-07 NO NO2020044C patent/NO2020044I1/no unknown
- 2020-12-08 FR FR20C1063C patent/FR20C1063I1/fr active Active
- 2020-12-09 HU HUS2000053C patent/HUS2000053I1/hu unknown
- 2020-12-14 CY CY2020041C patent/CY2020041I1/el unknown
- 2020-12-16 LT LTPA2020538C patent/LTPA2020538I1/lt unknown
- 2020-12-16 FI FIC20200050C patent/FIC20200050I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| HRP20140004T1 (hr) | Novi spojevi 951: bifeniloksipropanska kiselina kao crth2 modulator i intermedijeri | |
| HRP20121004T1 (hr) | (1-fenil-2-piridin-4-il)etil-esteri benzojeve kiseline kao inhibitori fosfodiesteraze | |
| JP2011500621A5 (hr) | ||
| CN116804007B (zh) | 普瑞利伟游离碱半水合物、其制造方法和用途 | |
| WO2008000483A3 (en) | Phenol derivatives for the treatment of respiratory diseases | |
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| NZ600790A (en) | Combination therapy for copd | |
| WO2011017201A3 (en) | Dp2 antagonist and uses thereof | |
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| HRP20200255T1 (hr) | Formulacija ac220 osušena raspršivačem | |
| MX2007005189A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3. | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| ATE521348T1 (de) | Kombination aus glycopyrrolat und einem beta2- adrenoceptor-agonist | |
| WO2007099553A3 (en) | 1,3-dioxane carboxylic acids | |
| HRP20171614T1 (hr) | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju | |
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
| JP2017513824A5 (hr) | ||
| JP2009541455A5 (hr) | ||
| HRP20192010T1 (hr) | Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja | |
| JP2016147914A (ja) | 上気道の疾患およびインフルエンザ症候群を治療するための組成物 | |
| WO2004058697A1 (en) | 4-nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivates and their pharmaceutical use | |
| WO2008137809A3 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof |